Absorbed dose per cycle (Gy) | ||||
---|---|---|---|---|
Expected assuming fixed biokinetics, ADE | Delivered, ADD | Ratio (ADD/ADE) | p value | |
Tumour | ||||
Cycle 1 | 15.6 (8.10–26.4) | 15.6 (8.1–26.4) | 1 | – |
Cycle 2 | 22.6 (10.6–35.6) | 11.4 (9.7–28.8) | 0.76 (0.42–1.00) | p > 0.05 |
Cycle 3 | 24.2 (10.9–34.8) | 11.3 (2.7–32.9) | 0.39 (0.25–0.94) | p > 0.05 |
Cycle 4 | 25.8 (11.3–40.8) | 4.3 (0.7–20.1) | 0.16 (0.02–0.92) | 0.013 |
Kidney | ||||
Cycle 1 | 1.40 (0.66–2.60) | 1.40 (0.66–2.60) | 1 | – |
Cycle 2 | 1.91 (0.89–3.34) | 1.39 (0.66–3.20) | 0.74 (0.69–1.02) | p > 0.05 |
Cycle 3 | 1.95 (0.87–4.26) | 1.71 (1.28–3.03) | 1.01 (0.35–2.03) | p > 0.05 |
Cycle 4 | 2.06 (1.02–3.86) | 2.40 (1.79–4.02) | 1.08 (0.84–1.76) | p > 0.05 |